Reactive carbonyl species and glycation intermediates (RCS)

Reactive carbonyl species (RCS) and glycation intermediates are highly reactive metabolic byproducts, including alpha-dicarbonyls like methylglyoxal (MG) and glyoxal, which are central to the non-enzymatic glycation process known as the Maillard reaction [PMID: 24511151]. These species are generated through various pathways, such as glycolysis, lipid peroxidation, and the degradation of glycated proteins, and their levels are significantly elevated under conditions of hyperglycemia and oxidative stress [PMID: 22531542]. RCS rapidly react with the amino groups of proteins, lipids, and DNA to form reversible Schiff bases and Amadori products (e.g., HbA1c), which subsequently rearrange into irreversible Advanced Glycation End-products (AGEs) [NIH: StatPearls - Glycation]. The accumulation of these intermediates and their resulting AGEs leads to structural and functional damage to tissues, contributing to the progression of diabetic complications, atherosclerosis, and neurodegenerative diseases like Alzheimer's [PMID: 30634418]. Pharmacological intervention typically involves "carbonyl scavengers" such as aminoguanidine or pyridoxamine, which trap these reactive species to prevent the formation of toxic AGEs [PubChem: Aminoguanidine]. However, therapeutic development has been hindered by safety concerns, such as the non-specific scavenging of essential carbonyls like pyridoxal phosphate (Vitamin B6) [PMID: 15159443].

Other names

DicarbonylsAlpha-oxoaldehydesGlycation precursorsMaillard reaction intermediatesReactive aldehydes

Carbonyl scavenging and inhibition of advanced glycation end-product (AGE) formation